Clinical Trial

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing management following neoadjuvant therapy with adebrelimab (anti-PD-L1) concurrent with chemoradiotherapy. The primary endpoint is 2-year overall survival rate in this watch-and-wait cohort.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-05.
Trial Details
NCT Number NCT06861894
Lead Sponsor Zhigang Li
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 164 participants
Start Date 2025-07
Primary Completion 2027-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-15